Search research articles
Contact Us
Filters
Showing results (1-10 of 58) with videos related to
Page
of 6
Sort By:
Diabetes & Vascular Disease Research
|
May 27, 2015
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
C David Sjöström, Peter Johansson, Agata Ptaszynska, et al.
Diabetes Research and Clinical Practice
|
April 19, 2023
Perspectives in weight control in diabetes - SGLT2 inhibitors and GLP-1-glucagon dual agonism
Nayyar Iqbal, Philip Ambery, Jennifer Logue, et al.
Journal of Diabetes
|
September 15, 2016
Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis
Wenying Yang, Linong Ji, Zhiguang Zhou, et al.
Diabetes, Obesity & Metabolism
|
August 24, 2016
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
Per Lundkvist, C David Sjöström, Sam Amini, et al.
Diabetes, Obesity & Metabolism
|
March 28, 2017
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
Per Lundkvist, Maria J Pereira, Petros Katsogiannos, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 18, 2017
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function
Sergei Petrykiv, C David Sjöström, Peter J Greasley, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
October 4, 2020
Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
Cristian Guja, Juan P Frías, Lisa Suchower, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
April 20, 2020
Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
Cristian Guja, Juan P Frías, Lisa Suchower, et al.
Diabetes Care
|
August 21, 2020
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
Serge A Jabbour, Juan P Frías, Azazuddin Ahmed, et al.
Journal of Diabetes and Its Complications
|
August 4, 2019
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials
Robert D Toto, Ronald Goldenberg, Glenn M Chertow, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 58) with videos related to
Sort By:
Page
of 6
Diabetes & Vascular Disease Research
|
May 27, 2015
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
C David Sjöström, Peter Johansson, Agata Ptaszynska, et al.
Diabetes Research and Clinical Practice
|
April 19, 2023
Perspectives in weight control in diabetes - SGLT2 inhibitors and GLP-1-glucagon dual agonism
Nayyar Iqbal, Philip Ambery, Jennifer Logue, et al.
Journal of Diabetes
|
September 15, 2016
Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis
Wenying Yang, Linong Ji, Zhiguang Zhou, et al.
Diabetes, Obesity & Metabolism
|
August 24, 2016
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
Per Lundkvist, C David Sjöström, Sam Amini, et al.
Diabetes, Obesity & Metabolism
|
March 28, 2017
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
Per Lundkvist, Maria J Pereira, Petros Katsogiannos, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 18, 2017
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function
Sergei Petrykiv, C David Sjöström, Peter J Greasley, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
October 4, 2020
Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
Cristian Guja, Juan P Frías, Lisa Suchower, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
April 20, 2020
Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
Cristian Guja, Juan P Frías, Lisa Suchower, et al.
Diabetes Care
|
August 21, 2020
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
Serge A Jabbour, Juan P Frías, Azazuddin Ahmed, et al.
Journal of Diabetes and Its Complications
|
August 4, 2019
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials
Robert D Toto, Ronald Goldenberg, Glenn M Chertow, et al.
Page
of 6